Revive Therapeutics Ltd.
๐จ๐ฆCanada
- Country
- ๐จ๐ฆCanada
- Ownership
- Public
- Established
- 2012-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.revivethera.com
Bucillamine in Treatment of Patients With COVID-19
- First Posted Date
- 2020-08-07
- Last Posted Date
- 2023-07-07
- Lead Sponsor
- Revive Therapeutics, Ltd.
- Target Recruit Count
- 713
- Registration Number
- NCT04504734
- Locations
- ๐บ๐ธ
Sweet Hope Research Specialty Inc, Hialeah, Florida, United States
๐บ๐ธColumbus Clinical Services, Miami, Florida, United States
๐บ๐ธEntrust Clinical Research, Kendall, Florida, United States
Bucillamine Phase 2 Trial in Patients With Cystinuria
- First Posted Date
- 2016-10-24
- Last Posted Date
- 2017-05-18
- Lead Sponsor
- Revive Therapeutics, Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT02942420
- Locations
- ๐บ๐ธ
New York University School of Medicine, New York, New York, United States
๐บ๐ธOmega Medical Research, Warwick, Rhode Island, United States
๐บ๐ธUniversity of Wisconsin School of Medicane and Public Health, Madison, Wisconsin, United States
Bucillamine for the Treatment of Acute Gout Flare in Subjects With Moderate to Severe Gout
- First Posted Date
- 2015-01-05
- Last Posted Date
- 2016-10-05
- Lead Sponsor
- Revive Therapeutics, Ltd.
- Target Recruit Count
- 66
- Registration Number
- NCT02330796
- Locations
- ๐บ๐ธ
Texas Physicians Research Medical Group, Arlington, Texas, United States
๐บ๐ธWest Coast Research, San Roman, California, United States
๐บ๐ธSun Research Institute, San Antonio, Texas, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath